The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis

References

• Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23:705–717. doi:10.5301/ejo.5000278.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the Pacific ocular inflammation study. JAMA Ophthalmol. 2013;131:1405–1412. doi:10.1001/jamaophthalmol.2013.4237.
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075–1087. doi:10.1016/j.ophtha.2017.12.039.
   PubMed Web of Science ®Google Scholar
• Li B, Li H, Zhang L, Zheng Y. Efficacy and safety of adalimumab in noninfectious uveitis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:899.
   Web of Science ®Google Scholar
• Hu Y, Huang Z, Yang S, Chen X, Su W, Liang D. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets’ disease-associated uveitis: a systematic review and meta-analysis. Front Pharmacol. 2020;11:941. doi:10.3389/fphar.2020.00941.
   PubMed Web of Science ®Google Scholar
• Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti–tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res. 2014;66:1073–1084. doi:10.1002/acr.22214.
   PubMed Web of Science ®Google Scholar
• Li Y, Mao X, Tang X, Mao H. Efficacy and safety of anti-TNFα therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatol Ther. 2021;8:711–727. doi:10.1007/s40744-021-00296-x.
   PubMed Web of Science ®Google Scholar
• Horiguchi N, Kamoi K, Horie S, et al. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome. Sci Rep. 2020;10:22227. doi:10.1038/s41598-020-78718-z.
   PubMed Web of Science ®Google Scholar
• Yepes-Nuñez JJ, Urrútia G, Romero-García M, Alonso-Fernández S. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Espanola Cardiol Engl Ed. 2021;74:790–799.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18:2127–2133. doi:10.11124/JBISRIR-D-19-00099.
   PubMedGoogle Scholar
• GRADEpro. https://gradepro.org/. Accessed September 10, 2021
   Google Scholar
• Cordero-Coma M, Calvo-Río V, Adán A, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. 2014;2014:e717598. doi:10.1155/2014/717598.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm. 2019;27:58–63. doi:10.1080/09273948.2017.1351573.
   PubMed Web of Science ®Google Scholar
• Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol. 2021;19:132. doi:10.1186/s12969-021-00630-1.
   PubMed Web of Science ®Google Scholar
• van BRE, Heslinga SC, Nurmohamed MT, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab — the GO-EASY study. J Rheumatol. 2019;46:153–159. doi:10.3899/jrheum.180312.
   PubMed Web of Science ®Google Scholar
• Yazgan S, Celik U, Işık M, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37:139–145. doi:10.1007/s10792-016-0239-y.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22:90–95. doi:10.3109/09273948.2013.844265.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46:95–101. doi:10.1016/j.semarthrit.2016.03.002.
   PubMed Web of Science ®Google Scholar
• Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018;36:652–657.
   PubMed Web of Science ®Google Scholar
• Elliott DB. The good (logMAR), the bad (Snellen) and the ugly (BCVA, number of letters read) of visual acuity measurement. Ophthalmic Physiol Opt. 2016;36:355–358. doi:10.1111/opo.12310.
   PubMed Web of Science ®Google Scholar
• Williams MA, Moutray TN, Jackson AJ. Uniformity of visual acuity measures in published studies. Invest Ophthalmol Vis Sci. 2008;49:4321–4327. doi:10.1167/iovs.07-0511.
   PubMed Web of Science ®Google Scholar
• Tsou BC, Bressler NM. Visual acuity reporting in clinical research publications. JAMA Ophthalmol. 2017;135:651–653. doi:10.1001/jamaophthalmol.2017.0932.
   PubMed Web of Science ®Google Scholar
• Tosi GM, Sota J, Vitale A, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37:680–683.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901–1914.e3. doi:10.1053/j.gastro.2017.02.004.
   PubMed Web of Science ®Google Scholar
• Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum. 2011;41:71–80. doi:10.1016/j.semarthrit.2010.08.005.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Jaffe GJ, Fortin E, et al. Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2021;128:899–909. doi:10.1016/j.ophtha.2020.10.036.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol Chic IL 1960. 2009;127:819–822.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–486. doi:10.1136/bjophthalmol-2012-302292.
   PubMed Web of Science ®Google Scholar
• Noriko O, Noriko O, Ayaka T, Junko H. Two cases of scleritis induced as a paradoxical reaction to CTLA4Ig. J Eye. 2020;37:636–639.
   Google Scholar
• AlBloushi AF, Alfawaz AM, Asrar AMAE. Implications of COVID-19 infection on patients with uveitis under biologic treatment. Br J Ophthalmol. 2021.
   Web of Science ®Google Scholar